logo
Share SHARE
FONT-SIZE Plus   Neg

Merck Reports New Data From 2 Pivotal Phase III Efficacy Trials For Suvorexant

Merck (MRK) announced new data from two pivotal Phase III efficacy trials for suvorexant, the investigational medicine company is developing for the treatment of insomnia.

In the studies, suvorexant significantly reduced the time it took patients to fall asleep and increased the time that patients stayed asleep as early as the first night and at the three-month time point compared to placebo. Merck noted that the investigational medicine met statistical significance for all primary endpoints except for one measurement at month 3 in one of the trials. These late-breaking data were presented today at SLEEP 2012, the 26th Annual Meeting of the Associated Professional Sleep Societies.

Darryle Schoepp, senior vice president and head of Neuroscience and Ophthalmology franchise, Merck Research Laboratories, stated, "Suvorexant approaches insomnia differently than other medicines because it helps patients to sleep by targeting and blocking orexins, which play a role in keeping people awake. We're excited about the Phase III results and the potential of suvorexant to become the first in a new class of medicines to help patients with insomnia."

by RTT Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

Quick Facts

Editors Pick
Computer and printer maker Hewlett-Packard Co. said Thursday after the markets closed that its second quarter profit fell 21% from last year, hurt by lower revenue and costs related to the planned separation of the company. However, the company's quarterly earnings per share, excluding items, came in above analysts' expectations, but its quarterly revenue fell short of analysts' forecast. Accounting software maker Intuit reported a plunge in third-quarter profit, hurt by impairment charges, even as results topped Wall Street estimates, driven by growth in small business segment amid a strong tax season. Struggling teen-apparel retailer Aeropostale Inc. (ARO), Thursday said its first-quarter loss narrowed from a year ago, driven largely by stronger margins even as revenues continued to plunge dropped. Nevertheless, the company lost almost one-fifth of its market value in after-hours trade, with the...
comments powered by Disqus
Follow RTT